|
|
|
|
|
Market Research Report
Repositioning ADME Studies: A Strategy to Reduce Drug Attrition
|
This publication has been discontinued on December 21, 2011.
Abstract
Introduction:
More effectively evaluating a broad range of a drug' s ADME properties during
the early stages of the R&D process provides an opportunity to reduce clinical
failure rates. This approach can enable researchers to eliminate poor drug
candidates early on, thereby substantially reducing the overall cost and risk
of drug development.
Get the Answers You Need to Shape Your Strategy:
- Even though drug developers are spending more resources on R&D, the number
of drugs approved each year is not increasing and the cost of development
continues to rise. What role do ADME properties of drugs play in their
success or failure? How can developers lower the attrition rate by moving
ADME studies to earlier in the development process?
- Repositioning of ADME studies and the use of new methodologies allow
companies to terminate unsuitable compounds, which improves R&D efficiency.
What screening tools are available and how can they help determine
viability of a compound so early in the development process?
- Outsourcing some or all of ADME testing is likely to be the preferred
option for many developers, especially smaller companies, and the choice of
service provider is a significant strategic decision. What commercial
opportunities are available for ADME testing service providers, and what steps
are these companies taking to create better, more useful ADME assays?
Scope:
ADME properties: Descriptions of the four categories of ADME:
absorption, distribution, metabolism, and excretion.
Positioning in R&D process: Benefits of moving ADME studies to earlier
in the drug development process.
Company profiles: Companies that provide ADME screening services and
tools to the pharmaceutical industry, including Apredica Creative Research
Solutions, and TechElan.
Outlook: How will companies implement ADME strategies in the future and
what new tools will become available?
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- ADME Properties and Drug-Likeness
- Positioning ADME in the R&D Process
- Absorption
- Experimental Methods
- Cell-Culture Assays
- Cell-Free Assays
- Computational Methods
- Distribution
- Protein Binding
- Blood-Brain-Barrier Penetration
- Metabolism
- Experimental Methods
- Computational Methods
- Excretion
- Company Profi les
- Apredica
- Creative Research Solutions
- Cyprotex
- Inpharmatica
- Nimbus Biotechnology
- Novamass Analytical
- Quest Pharmaceutical Services
- Solvo Biotechnology
- TechElan
- Outlook for Early-Stage ADME Studies
Tables
- 1. Lipinski' s Rules
- 2. Suppliers of Computational ADME Packages
- 3. Providers of ADME Services
Figures
- 1 Success Rates as Compounds Advance Through Stages of Development
- 2. New Positioning of ADME Studies During Drug Discovery
|
 |
